Arrowhead Pharmaceuticals (ARWR) EBITDA Margin (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of EBITDA Margin data on file, last reported at 191.57% in Q1 2026.

• Quarterly EBITDA Margin fell 26181.0% year-over-year to 191.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.67% (down 1393.0% YoY) and the FY2025 annual result came in at 11.86%, up 1693892.0% from the prior year.
• EBITDA Margin eased to 191.57% in Q1 2026, from 15.46% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 70.24% in Q1 2025 to a low of 6456.48% in Q4 2024.
• A 5-year average of 914.72% and a median of 208.26% in 2022 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 377789 bps — and 2025, when it soared 647194 bps.
• Tracing ARWR's EBITDA Margin over 5 years: stood at 67.36% in 2022, then tumbled by 5608 bps to 3845.25% in 2023, then slumped by 68 bps to 6456.48% in 2024, then jumped by 100 bps to 15.46% in 2025, then plunged by 1339 bps to 191.57% in 2026.
• The last three EBITDA Margin figures came in at 191.57% (Q1 2026), 15.46% (Q4 2025), and 17.2% (Q3 2025), per Business Quant data.